An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis. or A drug that is a form of thalidomide, and is used to treat multiple myeloma that has not gotten better with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Pomalidomide may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of immunomodulating agent and a type of antiangiogenesis agent. Also called CC-4047 and Pomalyst.